Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP.

Acta neuropathologica·2026
Same author

Characterizing the MRI signature of hippocampal sclerosis of aging.

Alzheimer's research & therapy·2026
Same author

Vulnerability of anterior medial temporal lobe subregions to early tau-related neurodegeneration in Alzheimer's disease: Converging evidence from tau-PET and plasma p-tau217.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Effects of Task-Irrelevant Talker Identity and Continuity on Spatial Selective Attention Under Interruption.

Trends in hearing·2026
Same author

Clinicoanatomic localization of iron-rich gliosis in aphasic presentations of globular glial tauopathy.

Brain communications·2026
Same author

Automated Imaging Differentiation for Dementia: Including Alzheimer Disease Dementia and Dementia with Lewy Bodies.

Neurology open access·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Christopher A Brown1, Sandhitsu R Das1, Katheryn A Q Cousins1

  • 1University of Pennsylvania, Philadelphia, PA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

患有阿尔茨海默氏症的个体表现出生物临床不匹配,特别是那些易受伤害的人,表现出加速的认知衰退和增加的α-synuclein共同病理. 这种tau-认知不匹配突出了不同的神经退行性模式,有助于识别有风险的人群.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 神经退行性疾病中的生物标志物
  • 阿尔茨海默氏症疾病的临床分期

背景情况:

  • 修订的阿尔茨海默氏病 (AD) 阶段包括生物临床不匹配,根据与生物阶段相对的临床损伤,将个人归类为脆弱或有弹性.
  • 这项研究使用了血p-tau217和18F-flortaucipir PET (T2) 生物标志物来评估与全球临床严重程度 (CDR-SB) 的不匹配.
  • 研究了大脑结构的差异,α-synuclein阳性,以及认知的纵向变化,tau积累和缩在正规,脆弱和弹性群体中.

研究的目的:

  • 用tau生物标志物 (p-tau217和Tau-MaX) 和临床严重程度 (CDR-SB) 来识别阿尔茨海默病中的生物临床不匹配.
  • 为了研究神经退行性差异,α-synuclein共同病理,以及规范性,脆弱和弹性群体的纵向轨迹.
  • 在一个独立的数据集中验证tau认知不匹配模型.

主要方法:

  • 包括具有可用的Tau PET或p-tau217和CDR-SB分数的粉素阳性ADNI参与者.
  • 使用线性回归来定义tau负担 (Tau-MaX或p-tau217) 和CDR-SB之间的不匹配,将参与者分为正规,脆弱和弹性组.
  • 分析了中间叶 (MTL) 结构,大脑范围厚度,α-synuclein状态和纵向tau PET,缩和认知轨迹,控制共变量. 在宾夕法尼亚州ADRC数据集中复制的发现.

主要成果:

  • 陶-马克斯和p-tau217都显示出与CDR-SB的中度关联.
  • 易受伤害的个体在前部MTL和temporolimbic区域表现出更大的神经退行以及更高的α-synuclein患病率.
  • 易受伤害的群体表现出加速的认知衰退,独立于积率和MTL和temporolimbic区域的更快的缩. 这些发现在ADNI和Penn ADRC数据集中是一致的.

结论:

  • 陶认知不匹配有效地识别出具有明显神经退行模式和α-synuclein共同病理的脆弱个体,与临主导的与年龄相关的TDP-43脑病变 (LATE) 重叠.
  • 基于等离子体的生物标志物在独立队列中成功识别了类似的脆弱个体,这表明临床实用性.
  • 这种方法完善了对AD进展异质性的理解,并确定了需要有针对性的干预措施的个体.